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Purpose: We aimed to assess the biological and clinical
significance of the human cysteine protease inhibitor cystatin M/
E, encoded by the CTS6 gene, in diseases of human hair and skin.
Methods: Exome and Sanger sequencing was performed to reveal
the genetic cause in two related patients with hypotrichosis.
Immunohistochemical, biophysical, and biochemical measurements
were performed on patient skin and 3D-reconstructed skin from
patient-derived keratinocytes.
Results: We identified a homozygous variant c.361C>T (p.
Gln121*), resulting in a premature stop codon in exon 2 of CST6
associated with hypotrichosis, eczema, blepharitis, photophobia and
impaired sweating. Enzyme assays using recombinant mutant
cystatin M/E protein, generated by site-directed mutagenesis,
revealed that this p.Gln121* variant was unable to inhibit any of
its three target proteases (legumain and cathepsins L and V). Three-
dimensional protein structure prediction confirmed the disturbance
of the protease/inhibitor binding sites of legumain and cathepsins L
and V in the p.Gln121* variant.
Conclusion: The herein characterized autosomal recessive hypo-
trichosis syndrome indicates an important role of human cystatin
M/E in epidermal homeostasis and hair follicle morphogenesis.
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INTRODUCTION
The importance of regulated proteolysis in epithelia and
execution of protease-mediated processes1–4 is well illustrated
by the identification of pathogenic variants in proteases and
their inhibitors in a variety of human cornification/hair
diseases (Supplementary Table S1 online).5–11 These include a
number of cysteine proteases of the lysosomal cathepsin
family and their cognate inhibitors of the cystatin family. In
addition, studies in mice have shown that misregulation of
proteolysis disturbs epidermal homeostasis, as witnessed by
for example cathepsin L deficiency,12,13 targeted ablation of
cathepsin D,14 and cystatin M/E deficiency.15
The protein encoded by the human CST6 gene (MIM
601891) was originally discovered independently by two
groups and named cystatin M or cystatin E (here further
referred to as cystatin M/E).16,17 Cystatin M/E is an atypical
cystatin in that it was found to inhibit both lysosomal
cysteine proteases such as cathepsin L (CTSL) and cathepsin
V (CTSV), and the asparaginyl endopeptidase legumain
(LGMN). We showed that cystatin M/E had an unusually
tissue-specific expression pattern with high expression levels
restricted to the skin.18 Our research on the function of this
protein led to the discovery that the phenotype of the
spontaneous ichqmouse mutant was caused by homozygosity
for Cst6 null alleles. The resulting cystatin M/E deficiency in
these mice causes disturbed epidermal cornification,
impaired barrier function, and neonatal lethality because of
excessive transepidermal water loss.15,19,20 Biochemical
evidence indicated that human and mouse cystatin M/E
controls the activity of several proteases and may indirectly
regulate activity of epidermal transglutaminases, which are
key enzymes in skin cornification.21 Using double knockout
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models in mice, we showed that a tightly regulated balance
between cathepsin L and cystatin M/E is essential not only
for tissue integrity of the epidermis, but also for maintenance
of healthy hair follicles (HFs) and corneal epithelium.22 Our
most recent data, in which we rescued the lethal skin
phenotype of cystatin M/E–deficient mice by transgenic,
epidermis-specific, re-expression of cystatin M/E under
control of the human involucrin promoter, showed that
cystatin M/E is not only a key molecule in a biochemical
pathway that controls stratum corneum (SC) homeostasis but
additionally plays an important role in maintaining HF
integrity.23
In the current study, we report for the first time a loss-of-
function (LOF) variant in the human CST6 gene, which
causes a novel autosomal recessive hypotrichosis syndrome.
MATERIALS AND METHODS
Patients
We ascertained a consanguineous Turkish family with
hypotrichosis, including three affected and four unaffected
individuals (Fig. 1a). All patients (PII:1, PII:2, and PIII:2)
were offspring of parents who were first cousins (in
generation I and generation II). Saliva samples for DNA
extraction were collected from all individuals. Biophysical
measurements were performed on the right upper ventral
forearm skin of PII:2 (father) and two healthy age-matched
male controls. Skin biopsies from these individuals were taken
from the same body location. Photographs were taken from
PII:2 (father) and PIII:2 (daughter, index patient). The
parents did not give permission to publish frontal facial
photographs nor was it allowed to take biopsies from the
index patient (PIII:2). We obtained informed consent from all
subjects using protocols approved by the local ethics
committee (CMO area Arnhem-Nijmegen), which comply
with the Declaration of Helsinki principles.
Infinium_CytoSNP_850K genotyping array analysis
DNA amplification, tagging, and hybridization were per-
formed according to the manufacturer’s protocol (Illumina).
Details of the procedure can be found in Supplementary
Materials and Methods.
Exome sequencing
Exome sequencing was performed on genomic DNA
extracted from the blood of the index patient (PIII:2). Details
of the procedure can be found in Supplementary Materials
and Methods.
Sequencing of the candidate gene
The pathogenic variant was confirmed in the patient by
Sanger sequencing (BigDye terminator v1.1 sequencing kit,
3730 DNA analyzer, Applied Biosystems) using primers
flanking exon 2 of CST6 (sense: 5’-AAGTGAGGAT-
CAAGGGTCAAGAC-3’, antisense: 5’-CAGTTCAGGATG-
GACAACCT-3’). Sequence data was visualized with Mutation
Surveyor (version 4.0.7, Softgenetics). Segregation analysis of
the pathogenic variant in all available family members was
performed.
Biophysical measurements
Details of the biophysical measurements (transepidermal
water loss, subcutaneous [SC] hydration, skin redness and
pigmentation) can be found in Supplementary Materials and
Methods online.
Development of 3D human epidermal equivalents
Primary human keratinocytes were isolated from biopsies of
family members PII:2 and II:3 and six healthy controls (wild-
type CST6, CST6+/+) and expanded according to the
Rheinwald–Green protocol.24 Passage 1–2 keratinocytes were
used to generate 3D epidermal equivalents as described
previously.25 The quality and phenotype of the epidermal
equivalents was investigated by morphology, protein expres-
sion (immunohistochemistry), and gene expression (quanti-
tative polymerase chain reaction [qPCR]). The reconstructed
epidermis was used to generate cell extracts to study protease
activity (enzymology) and cystatin M/E protein expression
(western blotting).
RNA isolation and qPCR analysis
A brief description of the procedure can be found in
Supplementary Materials and Methods. An overview of the
qPCR primer pairs used is shown in Table S2.
Morphological and immunohistochemical analysis
A brief description of the procedure can be found in
Supplementary Materials and Methods. An overview of the
antibodies used is shown in Table S3.
Protein extraction from epidermal equivalents
Proteins were extracted from the 3D epidermal equivalents. A
brief description of the procedure can be found in
Supplementary Materials and Methods.
Western blotting
Proteins were separated by SDS-PAGE using the NuPAGE
electrophoresis system and precast 12% Bis-Tris polyacryla-
mide gels under reducing conditions (Invitrogen). A brief
description of the procedure can be found in Supplementary
Materials and Methods.
Production of recombinant cystatin M/E variant p.Gln121*
Cystatin M/E variant p.Gln121* was obtained using the
recombinant plasmid pGEX2T-cystatin M/E and Quick-
change site-directed mutagenesis kit (Stratagene). Primers
used for the generation of the p.Gln121* variant were 5’-
GGCAGCAGGGGCGCAGTAGGAGAAGCTGCGC-3’
(sense) and 5’- GCGCAGCTTCTCCTACTGCGCCCCTG
CTGCC -3’ (antisense). Sequence analysis was performed
to check for the desired pathogenic variants in the
complementary DNA (cDNA). Production and purifica-
tion of recombinant wild-type and mutant forms of human
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cystatin M/E were performed as described previously.21
pGEX2T plasmids containing the wild-type or mutated
cystatin M/E cDNAs were transformed into Escherichia
coli BL21 Star (DE3) bacteria (Invitrogen). Cultures were
grown from one single colony overnight at 37 °C in LB
medium with ampicillin, followed by induction with
isopropyl-1-thio-β-D-galactopyranoside (Roche) at a final
concentration of 0.5 mM for 4 hours at 30 °C. Cells were
lysed by four cycles of freezing in liquid nitrogen and
thawing. Glutathione Sepharose 4B beads (Amersham
Biosciences) were used for purification of glutathione S-
transferase fusion protein from the lysate. Cleavage of the
fusion protein into glutathione S-transferase and cystatin
M/E occurred overnight at 4 °C using thrombin (Sigma) at
a thrombin to fusion protein ratio of 1:500 in a buffer
containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and
2.5 mM CaCl2. Recombinant cystatin M/E was purified
from glutathione S-transferase using glutathione Sephar-
ose 4B beads and dialyzed against phosphate-buffered
saline with a YM3 filter (Millipore). Protein concentration
was determined using a bicinchoninic acid (BCA) protein
assay (Pierce).
Fluorimetric enzyme assays
Protease inhibitor activity of recombinant human wild-type
cystatin M/E and the p.Gln121* variant against recombinant
human legumain,26 human CTSV, and human CTSL (both
from R&D Systems) was determined by measuring inhibition
of the proteases using fluorogenic synthetic substrates Z-Ala-
Ala-Asn-MCA (Peptides International) for legumain, and Z-
Leu-Arg-AMC (R&D Systems) for CTSV and CTSL. Protease
inhibition was measured after an incubation period of 5
minutes (CTSL) or 10 minutes (legumain and CTSV) at room
temperature. The buffer that was used in the legumain assay
contained 0.1 M phosphate (pH 5.7), 2 mM EDTA, 1 mM
dithiothreitol, 2.67 mM L-cysteine, and 5 µg/µl bovine serum
albumin. CTSV and CTSL assays were performed in a buffer
(pH 5.5) containing 0.1 M acetate, 1 mM ethylenediaminete-
traacetate (EDTA), 2 mM dithiothreitol, and 5 µg/µL bovine
serum albumin. Cathepsin and legumain protease activity was
I:1a b c
ed
f
II:1 II:2
III:1
c.361C>T;p.Gln121*
c.361C>T;p.Gln121*Cystatin M/E (CST6 )
Legumain
inhibitory domain
Cathepsin
inhibitory domains
Exon 1 Exon 2 Exon 3
1 149
α-helix β-sheets β-sheets
III:2
II:3
I:2
Fig. 1 Pedigree, clinical features, and schematic representation of CST6 loss-of-function (LOF) variant. (a) Pedigree and genotypes of the family
described. The homozygous LOF variant c.361C>T (p.Gln121*) was identified in individuals II:1, II:2, and III:2 (index patient), who were all born to
consanguineous parents. Index patient is indicated by the arrowhead. Squares, males; circles, females; black filled symbols, affected; the half-filled symbols
indicate heterozygous carriers of the CST6 variant. (b) The index patient (PIII:2) and (c) her father (PII:2) showed hypotrichosis due to progressive hair loss
from three years of age. (d,e) The father developed eczematous lesions later in life. (f) The homozygous nonsense variant c.361C>T (p.Gln121*) results in a
premature stop codon in exon 2 of the CST6 gene. The cystatin M/E (CST6) protein is 149 amino acids in size and the positions of the α-helix, the β-sheets,
and the cathepsin and legumain inhibitory domains are indicated.
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determined in protein extracts by measuring the hydrolysis of
fluorescent substrates as described above.
Structural modeling
The structure of human cystatin M/E in complex with
legumain has been solved experimentally and can be found in
Protein Data Bank (PDB) file 4N6O.27 This PDB file was
superposed on the structure of cystatin A in complex with
cathepsin V, which can be found in PDB file 3KFQ (not yet
published). Superposition of the assemblies and subsequent
analysis was performed using the MOTIF-alignment option in
the YASARA & WHAT IF Twinset.28,29
RESULTS
Clinical evaluation and genetic analysis
A 9-year-old girl (individual III:2 in Fig. 1a, index patient) was
referred to the clinical geneticist by a dermatologist because of
progressive hair loss resulting in hypotrichosis. Her father
(PII:2) and her uncle (II:1) showed great similarities with
regard to the clinical phenotype. The girl’s mother (II:3) and 6-
year-old sister (III:1) were unaffected. The girl’s parents and
her paternal grandparents had consanguineous marriages. The
paternal grandparents (I:1 and I:2) did not have any symptoms
of hypotrichosis. The clinical features of the index patient and
her father are summarized in Table S4. From birth both
suffered from a dry skin, blepharitis, and photophobia. After
three years the clinical phenotype of hypotrichosis appeared
(Fig. 1b, c). Overall body hair was sparse, very slowly growing,
and both patients had only a few eyelashes (not shown as no
permission was given to publish frontal facial photographs).
Later in life the father developed eczematous lesions on hands
(Fig. 1d, e) and feet (not shown). Both patients were not able
to sweat, except after extreme physical exercise.
High-resolution single-nucleotide polymorphism (SNP) array
did not show any pathogenic copy-number variants. After
pretest genetic counseling and consent of the index patient’s
parents, we performed exome sequencing. This analysis revealed
a homozygous nonsense pathogenic variant c.361C>T (p.
Gln121*) resulting in a premature stop codon in exon 2 of
the CST6 gene (Fig. 1f). We confirmed this pathogenic
variant with Sanger sequencing in the index patient and other
family members. The results were consistent with
autosomal recessive inheritance of c.361C>T as the causative
pathogenic variant. The father of the index patient, who had
very similar symptoms, was also found to be homozygous for
the variant. All clinically unaffected family members were
heterozygous.
Epidermal acanthosis and abnormal distribution of stratum
corneum water content
To investigate the biology underlying the phenotype of
cystatin M/E deficiency in this family, we first performed
several noninvasive biophysical measurements on the mid-
ventral forearm skin of patient PII:2 (father) to detect possible
abnormalities. Transepidermal water loss measurements in
this patient were comparable with healthy controls, indicating
no difference of inside-out skin barrier function (Table S5).
Interestingly, spectrophotometric determination of skin red-
ness and pigmentation showed that the a* value was
increased in the patient, demonstrating the presence of
erythema. Pigmentation (b* value) was normal. In vivo
reflectance confocal microscopy (RCM) measurements
showed a thickened epidermis (acanthosis) as well as a
thickened SC in the cystatin M/E–deficient patient (Table S5).
The water content of the patient’s SC was comparable with
healthy controls (Fig. 2a). However, the water content pattern
of the patient was more heterogeneous compared with the
controls (Fig. 2b, c). This finding indicates a different
distribution of water content in the SC, which can explain
the dry skin.
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Fig. 2 Heterogeneous stratum corneum hydration in patient skin. (a) Permittivity measurements (bars represent mean +/-SD) of the patient and the
healthy controls, demonstrating no overall quantitative difference between the patient and healthy controls. (b) Epsilon subcutaneous (SC) hydration image
of the patient skin, showing a more heterogeneous water content pattern depicted by the larger black spaces (low SC hydration, representing the absence
of water) between the green islets (high SC hydration, indicating the presence of water). (c) Epsilon SC hydration image of a healthy control, with small black
areas between the homogeneous green islets, indicating a homogeneous distribution of the water content in the SC.
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Abnormal epidermal proliferation and differentiation, and
atypical dermal collagen fiber density
For in-depth phenotypical characterization we microscopi-
cally analyzed the skin biopsies. Hematoxylin and eosin
(H&E) staining confirmed the RCM findings that the
epidermal and SC thickness of the patient was increased as
compared with six healthy controls (Fig. 3a, b). H&E staining
also showed stronger eosinophilic collagen fibers in the
papillary dermis of the patient’s dermis compared with
healthy control dermis. This was even more prominent in an
Elastica van Gieson stained section, which showed densely
packed collagen fibers in the patient’s papillary dermis
(Fig. 3c, d). Protein expression analysis revealed the presence
of cystatin M/E in the upper granular layer of the epidermis
(Fig. 3e, f) suggesting that the truncated protein was
expressed. The increased number of proliferating cells,
represented by Ki67 staining (Fig. 3g, h), was consistent with
the increased epidermal thickness. We observed an increased
protein expression of epidermal differentiation genes like
filaggrin (FLG), loricrin (LOR), and involucrin (IVL) in the
patient’s skin (Fig. 3i–n). The expression of transglutaminase
1 (TGM1), an enzyme responsible for crosslinking structural
proteins of the cornified envelope in epidermal keratinocytes,
was clearly induced in the upper epidermal layers of the
patient (Fig. 3o, p). The increased expression levels of Ki67,
TGM1, and the three differentiation genes were confirmed at
the messenger RNA (mRNA) level (Supplementary Figure S1).
To explain the observed increased redness (erythema) of the
patient’s skin, we evaluated CD31 expression (endothelial cell
marker) as a marker for angiogenesis but no differences were
found when compared with healthy controls (data not
shown).
Disrupted protease binding sites in cystatin M/E p.Gln121*
The presence of cystatin M/E protein in the epidermis of the
patient (Fig. 3e, f) indicated that the c.361 C>T pathogenic
variant did not preclude translation of a (truncated) protein.
Based on the known protease binding sites of cystatin M/E
(Fig. 1f), we hypothesized that truncation of the protein
would lead to a compromised inhibitory activity of cystatin
M/E against cathepsins L and V. To study the functional
consequences of the c.361 C>T pathogenic variant, we
generated recombinant truncated cystatin M/E (p.Gln121*)
by site-directed mutagenesis. Wild-type and mutant cystatin
M/E were tested for inhibitory activity against several
cathepsins and legumain. Ki values were determined using
an Easson–Stedman plot as previously described.21 When the
Ki could not be determined in case of very low affinity, the
ratio of protease activity in the presence (Vi) and absence (V0)
of inhibitor was determined, and the remaining protease
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Fig. 3 Morphological and histological analysis of CST6 loss-of-function (LOF) skin. Midventral forearm skin biopsies obtained from patient PII:2 (1st
and 3rd column) and two healthy controls (2nd and 4th column) were examined for morphology and protein expression. Hematoxylin and eosin staining
showed acanthosis and dense collagen fibers in the papillary dermis (a, b), which was confirmed by Elastica van Gieson staining (c, d). Cystatin M/E
expression was present in the stratum granulosum (e, f). Induced expression was found in the patient skin for the proliferation marker Ki67 (g, h), epidermal
differentiation proteins filaggrin (i, j), loricrin (k, l) and involucrin (m, n), and the crosslinking enzyme transglutaminase 1 (o, p). Scale bar represents 400 µm.
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Fig. 4 3D visualization of the cystatin M/E–legumain–cathepsin V complex. The visualization was made by superposing Protein Data Bank (PDB) files
4N6O and 3KFQ. Legumain and cathepsin V are shown in purple and magenta respectively. Cystatin M/E is colored by element (β-strands= red, ɑ-helix=
blue, loops= cyan/green). The residues deleted after truncation of the protein are colored gray. (a) Overview of the complex in ribbon presentation. (b)
Overview of the complex with protein surface shown. (c) Close-up of the protein–protein interaction sites with side chains of the residues shown.
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Fig. 5 Analysis of CST6 loss-of-function (LOF) 3D epidermal equivalents. (a) Hematoxylin and eosin (H&E) staining showed no specific morphological
differences between epidermal constructs generated with primary keratinocytes that harbor a homozygous or heterozygous CST6 p.Gln121* variant
compared with the wild-type control(s). Cystatin M/E protein is expressed in the stratum granulosum of all constructs. Scale bar represents 400 µm. (b)
Western blot analysis of cell extracts derived from normal healthy skin biopsies (lane 1) and from epidermal equivalents from healthy controls (lanes 2 and 3),
the patient (PII:2, father) with the homozygous CST6 p.Gln121* LOF variant (lane 4), and the healthy mother (II:3) who is heterozygous for the variant (lane
5). CST6trunc= truncated cystatin M/E, CST6glyc= glycosylated cystatin M/E, CST6wt=wild-type cystatin M/E. (c) Conversion of the fluorogenic z-A-A-N-
AMC substrate. Cell extract of the patient-derived construct contains more free legumain activity compared with controls.
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activity at a fixed high inhibitor (I) concentration (300 nM)
was calculated. Ki values of wild-type human cystatin M/E
and the p.Gln121* variant for interaction with human
cathepsins and human legumain are shown in Table S6.
Wild-type cystatin M/E is a high affinity inhibitor for
cathepsin L, cathepsin V, and legumain as witnessed by their
respective Ki values of 1.78 nM, 0.47 nM, and 0.25 nM,
21
whereas cathepsin B is not inhibited by human cystatin M/E
(vi/v0 > 0.71 at [I]= 300 nM). The Ki value of the p.Gln121*
variant for interaction with cathepsins L and V could not be
determined (vi/v0 > 0.86 and vi/v0 > 0.98 respectively at [I]=
300 nM), which indicates that the recombinant mutated
variant was not able to inhibit any of these cathepsins. As the
legumain inhibitory domain is positioned in the first exon
(Fig. 1f) we anticipated that legumain inhibitory activity
would be retained. This, however, was not the case as no
inhibition was observed by the p.Gln121* variant (vi/v0 > 1.09
at [I]= 300 nM). As a control we used heat-inactivated
wild-type recombinant cystatin M/E showing that this
denaturated protein was not able to inhibit both cathepsins
and legumain.
Based on the position of the pathogenic variant (Fig. 1f) at
the proximal end of exon 2 and just before two of the four β-
sheets, we hypothesized that the protein structure of the
truncated protein had changed, resulting in an inactive
molecule. Indeed, 3D-modeling using the published X-ray
crystal structures of the cystatin M/E–legumain (PDB file
4N6O) and cystatin A–cathepsin V (PDB file 3KFQ)
complexes indicates that the p.Gln121* pathogenic variant
will severely affect the protein structure and function (Fig. 4).
According to the created in silico model of the complex,
legumain and cathepsin V both seem to bind to their own
distinct sites on cystatin M/E. However, both sites require
interactions with residues located in the last two β-strands
(direct), or with residues that are correctly positioned by those
residues in the last two β-strands (indirect). As a result, the
deletion of these β-strands caused by pathogenic variant p.
Gln121* will affect these binding sites and thereby affect the
interaction with other proteins.
Free legumain activity in cystatin M/E–deficient 3D skin
equivalents
Because cystatin M/E is known to target three proteases—
cathepsin L, cathepsin V, and legumain, all of which are
expressed in human epidermis and HFs—we tried to assess
the contribution of unrestricted activity of these proteases due
to the p.Gln121* variant. Therefore, we generated 3D
epidermal equivalents from the patient’s keratinocytes
(PII:2, homozygous CST6 p.Gln121*), keratinocytes from
the unaffected mother (II:3, heterozygous CST6 p.Gln121*),
and keratinocytes from healthy individuals (N= 6, homo-
zygous CST6 wild type). Similar to the in vivo biopsy material
of PII:2, we observed cystatin M/E protein expression in the
stratum granulosum of the homozygous CST6 p.Gln121*
epidermal equivalents (Fig. 5a). Western blot analysis
revealed the expression of a truncated protein of
approximately 10 kDa in cell lysates of the p.Gln121*
epidermal equivalent (Fig. 5b). The heterozygous p.Gln121*
epidermal equivalent expressed both truncated and wild-type
cystatin M/E as indicated by two bands, one at 12 kDa and
one at 10 kDa (Fig. 5b). The 16-kDa bands indicate the
presence of glycosylated cystatin M/E in the 3D epidermal
equivalents. Clearly, the truncated cystatin M/E is not
glycosylated as the presumed glycosylation site carrying an
N-linked carbohydrate chain at position 137Asn is deleted
due to the p.Gln121* variant.17 In contrast to in vivo skin we
could not detect differences in the expression of specific
genes/proteins involved in differentiation and proliferation
(not shown). Protease activity measurements in the cell
extracts of these epidermal equivalents indicated that
cathepsin L and cathepsin V activity was low to undetectable
in all epidermal equivalents (not shown). Strikingly, we found
a high level of legumain activity in the patient-derived CST6
p.Gln121* epidermal equivalent compared with six control
CTS6 wild-type epidermal equivalents (Fig. 5c). Although this
finding did not allow unequivocal identification of the
relevant protease responsible for the pathological alterations,
it is consistent with the observation that legumain inhibitory
activity is lost in the p.Gln121* variant.
DISCUSSION
Our previous genetic studies in mice and in vitro biochemical
studies using human enzymes and inhibitors have provided
information on the role of cystatin M/E in epidermal
cornification (Figure S2A). Based on the phenotype of the
cystatin M/E–deficient ichq mice, and the biochemical and
cell biological properties of human cystatin M/E, we
anticipated that deficiency in humans would cause a severe
ichthyosis-like phenotype rather than a hair phenotype. For
this reason we have previously sequenced the CST6 gene in a
large number (>100) of patients with autosomal recessive
congenital ichthyosis who were negative for variants in known
ichthyosis-associated genes. In none of these patients did we
detect variants in the coding sequences of the CST6 gene.30
Although the patients described here do have a mild
epidermal phenotype, their hypotrichosis is the most
prominent and serious clinical feature, and led us to classify
this syndrome as a heritable hair disease rather than an
ichthyosis.
The clinical skin phenotype of the two patients was less
severe than we expected based on our mouse studies and
in vitro knockdown experiments.15,22,23,30 The severe and
lethal skin phenotype in ichq mice, where the protein is
completely absent, might be due to larger quantities of body
hair, compared with humans, because neonatal keratinization
of the HFs and subsequent dehydration is a hallmark of these
mice. In the current study we show that the patient’s
keratinocytes still produce a significant amount of truncated
protein, which is unable to inhibit protease activity. However,
this truncated protein may still have some hitherto unknown
functions that are important for a proper development of the
epidermis, as complete short hairpin RNA (shRNA)-mediated
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knockdown of cystatin M/E in a human skin equivalent
showed a more severe phenotype.30
We herein show abnormal epidermal proliferation and
differentiation, and atypical dermal collagen fiber density in
skin biopsies of the patient, features that we did not or could
not observe in the in vitro epidermal equivalents generated
with the patient’s keratinocytes. These differences between the
in vivo and in vitro situation are likely due the fact that the 3D
skin model used here only contains keratinocytes in a sterile
environment, thereby lacking interactions with skin microbes,
fibroblasts, and/or other dermal and epidermal cells. Potential
microbe–host or immune cell–mediated interactions may
cause the phenotypical characteristics seen in our patient. Of
note, there is currently no in vitro model available to grow
hairs from epidermal keratinocytes, which precluded inves-
tigation of the hair phenotype in vitro.
Despite the fact that skin biopsies were taken from
macroscopically healthy skin, histopathology and immunos-
taining revealed epidermal hyperproliferation and mildly
abnormal differentiation compared with normal skin from
healthy volunteers taken from the same anatomical location.
Obviously it has to be taken into account that we could only
study histology of one single patient (the father but not the
daughter), and the observed abnormalities may be within the
normal range. The dry skin observed in the two patients and
the distribution of the SC water content were clearly abnormal
compared with what is observed in healthy controls. It has to
be noted that both patients had atopic eczema-like lesions,
which may be mechanistically related to their dry skin.
Speculatively, cystatin M/E deficiency may yet be another
example of an epidermal defect that predisposes to atopic
eczema, as has been reported for variants in filaggrin and
genes that lead to a disturbed protease/inhibitor balance
resulting in an aberrant skin barrier function.31–33 Observa-
tions in rare skin barrier diseases, for which there are now a
few examples, will lend further support to initiatives to
prevent atopic disease by strengthening skin barrier function
in early life.
We demonstrated that due to the c.361 C>T LOF
npathogenic variant in the CST6 gene, the resulting truncated
cystatin M/E protein is unable to inhibit legumain and the
cathepsins L and V. As all three proteases are expressed in the
human HF and also colocalize with cystatin M/E in the distal
part and infundibulum of the HF34 (see Figure S2B), it is
likely that unrestricted activity of these proteases is the cause
of hypotrichosis in patients. Our previous animal studies in
double knockout mice and transgenic mice revealed that
unrestricted cathepsin L activity is responsible for ichthyosis
and lethality in the ichq mouse, but not for the persistent
alopecia and fibrotic changes.22,23 However, it should be noted
that the cystatin M/E controlled biochemical pathway in mice
is distinct from humans. Mice do not have a cathepsin V
orthologue, and we showed that mouse cystatin M/E differs
from the human protein at amino acid position 64 (Asn
instead of Asp), which renders it inactive against legumain.
Ablation of legumain in mice with a cystatin M/E–deficient
background (Cst6−/−Lgmn−/−) did not allow survival beyond
the neonatal phase and mice displayed exactly the same
phenotype as ichq mice. Human cystatin M/E, however, is a
specific and high affinity inhibitor of human legumain. In the
current study we found free legumain activity in an extract of
the epidermal construct generated from patient keratinocytes,
which was more than fourfold higher than in control
keratinocytes (Fig. 5c). This suggests that cystatin M/E is a
major inhibitor of epidermal legumain activity. We were
unable to quantitatively assess the effect of cystatin M/E
deficiency on cathepsin L and V activities because no activity
could be detected in mutant or wild-type cell extracts. We
surmise that activity of these enzymes is masked by the
presence of other inhibitors in the extracts, such as hurpin
and the cystatins A, B, and C.21,35 Due to the lack of material
from the patient (e.g., biopsy material including HFs) and the
limitations of our 3D model (no hair growth) we are, at this
point, not able to dissect the mechanism in more detail or
identify the key protease that causes the hypotrichosis.
Our previous animal work has also shown evidence that free
cathepsin L activity is responsible for the eye pathology in
cystatin M/E–deficient mice.22 These mice developed severe
keratitis, thickening of the corneal stroma, and squamous
metaplasia of the corneal epithelium. The patients presented
in the current study also have clinically relevant eye problems,
although milder than in the mice, such as dry eyes,
blepharitis, and photophobia. If these problems are also
caused by unrestrained cathepsin L activity this might provide
therapeutic opportunities.
In conclusion, we have identified a new autosomal recessive
hypotrichosis syndrome caused by a LOF pathogenic variant
in the CST6 gene. These findings provide another example of
the importance of protease–antiprotease balance in the
regulation of epidermal and hair follicle homeostasis.
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